Abstract

Triple-negative breast cancer (TNBC) is the most lethal subset of breast cancers, lacking targeted therapies. There is a critical need to identify alternative treatments for TNBC. Towards this, in this research, we investigated the anticancer effects of Galloflavin (GF), an LDHB inhibitor, in reducing the proliferation of MDA-MB-231, the human triple-negative breast cancer cells. To enhance the uptake of GF, we applied electrical pulses (EP) with GF and studied its protein profile characteristics and viability. We used GF at a concentration of 100μM with 800V/cm, 100μs, and eight electrical pulses to treat these cells. Label-free, high throughput, quantitative proteomics results indicated that 172 proteins were significantly downregulated, while 222 proteins were significantly upregulated. The upregulated proteins include Cytochrome C Oxidase Assembly Factor and Mitochondrial Ribosomal proteins. Key downregulated proteins include LDHB, and ENO1 in EP+GF treatments, compared to GF only, indicating the effect of EP+GF combination in reducing the proliferation of the TNBC cells. These results pave the path for additional therapy for TNBC and the various pathways the TNBC cells proceeded with Electrochemotherapy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call